Tobira Therapeutics to Participate in Two Conferences in June

SOUTH SAN FRANCISCO, Calif., May 31, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in June.

• Jefferies 2016 Healthcare Conference
  • Presentation date: Thursday, June 9, 2016
  • Presentation time: 4:30 p.m. ET
    
    
• JMP Securities Life Sciences Conference
  • Presentation date: Tuesday, June 21, 2016
  • Presentation time: 3:30 p.m. ET

A live webcast and 30-day archive of these presentations will be available at http://ir.tobiratx.com/. 

About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and as an adjunctive therapy to standard of care in HIV. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

SOURCE Tobira Therapeutics, Inc.

Related Links

http://www.tobiratherapeutics.com/